Device Congress. Track B: Reimbursement. How to Convince the Medical Director Your Product is Special

Similar documents
The Fundamentals of Reimbursement

Market Access Strategy and Planning: Succeeding in the Age of Value-based Reimbursement

MEDICAL DEVICE REIMBURSEMENT PRESENTED AT ST. THOMAS UNIVERSITY, DESIGN AND MANUFACTURING IN THE MEDICAL DEVICE INDUSTRY COURSE ON SEPTEMBER 30, 2013

Pre Market Reimbursement Strategies for New Technologies

The Impact of Future Healthcare Reform on MedTech Communications

ASSESSING THE VALUE OF MEDICAL DEVICES CHOOSING THE BEST PATH FORWARD: WHERE DO WE GO FROM HERE? Drew Baker GO FROM HERE?

MedTech/BioTech Reimbursement: Getting Paid in the USA. MDCC Greater MSP September, 2016

Pricing and Reimbursement Strategies for Diagnostics

Ace Left Brain Stimulation Device Strategy for Medicare Coverage and Payment

INSTITUTE OF MEDICINE COMMITTEE ON THE DETERMINATION OF ESSENTIAL HEALTH BENEFITS

Fifth Annual National Congress on Health Care Compliance. Pharmaceutical Sales and Marketing: Are You Afraid to Look Under the Rocks?

Disease Management and the Medicare Drug Benefit: Opportunities and Threats for the Pharmaceutical Industry

Problems with Current Health Plans

2018 Predictive Analytics in Healthcare Trend Forecast

Financial and Operational Benchmarking Trends & Techniques

Leveraging Real-World Data and Analytics in the Device Industry. Tom Abbott Head, Healthcare Informatics Medical Device & Diagnostics

Investor Presentation. August 2007

Understanding Private Payers & Maximizing Private Payer Reimbursement Strategies: Understanding the Process

The Changing Landscape of Medicare's Clinical Trial Coverage Policies for Medical Devices. Michael Sanchez, M.A., CCA Reimbursement Advisor

Re: Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of- Pocket Expenses [CMS-4180-P]

Digital Health Reimbursement: Getting Paid in the USA

Overview of Reimbursement Strategies for Novel Medical Technologies

Avalere Health 2015 Industry Outlook

Lindsey Imada, PharmD Candidate 2016 Midwestern University, Chicago College of Pharmacy

Coding and Payment for Genomic Sequencing Procedures (GSPs) and Existing Advanced Diagnostic Laboratory Tests (ADLTs)

OHSU Center for Evidence-based Policy Rhonda Anderson, RPh Director of Pharmacy EMPAA 2017 October 30, 2017

Managing the risk and unpredictable costs of transplants

P&T Committee and monograph preparation. Dr. Coreen Montagna, PharmD

Coding and Reimbursement

Clinical Trials Corporate Medical Policy

Provide sufficient incentive for providers to maximize health outcomes and value while reducing costs;

HEALTH SPENDING AND REFORM IMPLEMENTATION OCTOBER 2011

Physical Therapy Facility Application

The Regulatory & Reimbursement Policy Landscape in Personalized Medicine: A (Payer s) Perspective

Compensation and Reimbursement

RISK SHARE AGREEMENTS

PERFORMANCE AND TRAJECTORY

REPORT OF THE COUNCIL ON MEDICAL SERVICE

Will Health Plans Kill the Laboratory Outreach Program?

GOVERNMENTAL AFFAIRS AND LEGAL MATTERS (A)

Table of Contents. Summary of Senator John McCain s Health Care Platform Summary of Senator Barack Obama s Health Care Platform.

KPIs & KEIs for Success

Putting the Pieces Together, a Review of the Benefits Investigation Process. Thomas Cohn, Asembia

Members: Abbott, Blue Cross Blue Shield of Massachusetts, Boston Scientific Corporation, Genentech, Inc., Medtronic, Inc., Premier, Inc.

Unlocking Growth in China Challenges and Opportunities. Yehong Zhang, PhD, MBA, Country Manager, IMS Greater China

2008 Medicare Part D: Pharmacist's Survival Guide. Ronnie DePue, R.Ph., CGP

OHSU Center for Evidence-based Policy Rhonda Anderson, RPh Director of Pharmacy National Conference of State Legislators San Diego, CA December 10,

Teva Neuroscience and the National Multiple Sclerosis Society. Announce Release of Multiple Sclerosis Trend Report

The Physician-Owned Management Services Organization

Health Plan Design Options August 23, 2012

FAQ. 1. Will Single Payer cost my company more? Will there be a tax increase associated with Single Payer?

Medical Device Regulatory, Reimbursement and Compliance Congress. Steve Ubl President and CEO AdvaMed

Financial and Operational Benchmarking

VALUE-BASED HEALTH AWARDS. Steve Priddy Executive Director, Value-Based Health

PhRMA Perspective: Government Policies to Support Innovative Contracting Approaches

Paul Lorenz, MBA Chief Executive Officer, SCVMC. Continuing Medical Education (CME) Standards for Commercial Support

Moderator: J van Loon,MSc Mapi. Advisor to the President, Head of International Affairs, HAS France

Welcome. AMCP Partnership Forum. Designing Benefits and Payment Models for Innovative High Investment Medications

Sunshine and Aggregate Spend

Building Clinical Trial Revenue Integrity Compliance Through Auditing and Understanding Payer Requirements

Value-Based Pricing: The Good, The Bad, and The Ugly

Challenges in High Dollar Drugs. Suzanne Francart, PharmD, BCPS Manager Infusion Services & Medication Assistance Program UNC HealthCare

The Cost of Specialty Drugs: Payer Perspectives

A VISIBLY DIFFERENT APPROACH TO PHARMACY BENEFITS FOR GOVERNMENT

Society of Professors of Child and Adolescent Psychiatry. Michael Jellinek, M.D. May 9, 2013

THE $10,000 QUESTION: TACKLING THE COMPLEXITIES OF VALUE-BASED PHYSICIAN COMPENSATION

Introducing. Manulife DrugWatch. Applying rigorous oversight to help ensure value for money in a dramatically changing drug market

DPC as THE Advanced Alternative Payment Model

William Blair 35 th Annual Growth Stock Conference. June 9, 2015 NYSE: Q. Copyright 2014 Quintiles

Provider Strategies Required to Succeed in a Consumer Driven Health Care Environment

PRESCRIPTION MEDICINE PRICING OUR PRINCIPLES AND PERSPECTIVES

BCBS National Clinical Innovation Acceleration Driving Smarter, Better Healthcare in Every Local Community

PAY-FOR-PERFORMANCE: THE PROMISE AND CHALLENGES OF OUTCOMES-BASED PHARMACEUTICAL CONTRACTING

BioMarin RareConnections Patient Enrollment Form for CLN2 Disease

Policies Targeting Administrative Simplification. Harry Reynolds Blue Cross Blue Shield of North Carolina

Provider Manual Section 12.0 Outpatient Pharmacy Services

FINANCIAL CONFLICT OF INTEREST POLICY

METHODOLOGY NOTES. TRANSPARENCY DISCLOSURE FOR TRANSFERS OF VALUE (ToV) TO HEALTHCARE PROFESSIONALS (HCP) AND HEALTHCARE ORGANISATIONS (HCO)

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

Reporting of Transfers of Value to HCPs and HCOs Methodological Note for Reporting of 2017 Data in 2018

HEALTHCARE: INTRODUCTION MAIN ISSUES IDENTIFIED BY THE COMMITTEE:

Understanding the Insurance Process

Coverage Analysis and Research Billing Beyond SOC vs. Study Paid. March 14, 2014

Precision Medicine. A Health Economic perspective

Questions and Answers. When should I use mail order pharmacy services? What is my co payment for drugs? What is my co payment for preferr

Sutter Medical Network

Pharmaceutical Market Trends

PURPOSE: To establish minimum criteria for a supplier to considered for a HealthTrust contract.

Future Trends Affecting the Pharma, Biotech and Device Industries

4/8/17. The Changing Nature of Physician Payment and Health Care Reform in The AMA A Unifying Voice for Physicians

With those goals in mind, we wish to specifically address enteral nutrition.

Q SPECIAL TOPIC REPORT: PROVIDER-OWNED HEALTH PLANS

Managing Specialty Pharmaceuticals: Balancing Access and Affordability

REPORT OF THE COUNCIL ON MEDICAL SERVICE. Prior Authorization Simplification and Standardization (Resolutions 705-A-15 and 712-A-15)

Ensure Network Adequacy. May 23, 2017

Milliman Healthcare Services

Risk Adjusted Episodes as Benchmarks for ACOs: A Society of Actuaries Sponsored Study

Health Care Reform in the United States

Redefining Health Care: Creating Value-Based Competition on Results

PRESCRIPTION DRUG SPENDING IN THE U.S. HEALTH CARE SYSTEM: AN ACTUARIAL PERSPECTIVE

Transcription:

Track B: Reimbursement How to Convince the Medical Director Your Product is Special Michael Becker, GM Global Reimbursement, GE Healthcare Michael Bihari, MD, Health Care Consultant March 29, 2007

Key Questions We Will Address Today What are the do s and don ts in convincing the payers medical directors that your product is worth covering and reimbursing? What are medical directors looking for? How do they make decisions? And what are some strategies one successful medical company uses? 2

Before We Start... What is your Reimbursement Strategy? Where does discussion w/medical Director fit in your overall reimbursement strategy? Medical Director is just one stakeholder Medical Director may influence coverage decisions... don t forget about coding & payment 3

GEHC Reimbursement Program

Reimbursement Objectives 1. Accelerate reimbursement for new products 2. Respond to customer needs for existing products 3. Develop & advocate public health policies favorable to GEHC products 5

Reimbursement Objective #1 Reduce cycle time from product launch to customer paid & patient access Existing Procedure Existing Coding/Coverage/Payment Regulatory Approval New Procedure New Code (15 mos. min) New Payment (1-2 yrs) Expanded Coverage (1-5 yrs) $ Customer Paid + Improved Health Outcomes 0-7 years 6

Creating Surround Sound With Key Stakeholders Technology Assessmt Coverage support for payers based on clinical evidence Consumers/Patients Advocate access to technology through favorable coverage & appropriate payment Professional Societies Code application & utilization guidance, coverage support, clinical guidelines Coverage CMS Priv Payers Legislature Coding AMA CMS Payment CMS Priv Payers Industry Organizations Coverage and payment support, industry PR and collaboration opportunities Lobbying Lobby for coverage, protect payment Providers Petition for code, advocate for coverage, payment, protect payment Manufacturers New product reimbursement strategy, work w/payers on coverage & payment Employers Advocate for access to technology that increases quality and lowers costs 7

We Will Be Successful, If We Can Create Positive, Ongoing Dialogue With Payers Objectives of Payer Focus Understand coverage & payment policy processes (decision makers, influencers, requirements, timing, communication) and where we can influence Gather payer input into product reimbursement strategies: clinical trial design, reimb. tactics to support coverage Collaborate with payers to accelerate coverage for new technology, where appropriate 8

We Will Be Successful, If We Can Create Positive, Ongoing Dialogue With Payers Objectives of Payer Focus Develop relationship w/ major payers for open communications when favorable/unfavorable policy changes made (coverage, payment, utilization) Gather payer input on product development how to meet their needs (VBM/P4P data, pricing transparency; reducing medical errors; linking claims data w/ pt. history; provider accreditation) Identify opportunities to collaborate on major health policy initiatives (IT initiatives, VBM/P4P, Quality) 9

Meeting With Medical Director Preparing for the meeting Inventory payer relationships Select target payers Research target payer policies/positions Assemble clinical value story (WIIFM) Assess existing evidence 10

Meeting With Medical Director Preparing for the meeting Assess provider & professional society support Prepare agenda & presentation Determine/secure meeting participants Modify Reimbursement Strategy accordingly Maintain dialogue with payer 11

Meeting With Medical Director Who should attend the meeting? Practicing physician Technical expert Clinical trials design expert Senior company representative Consultant / Facilitator No Sales & Marketing 12

Meeting With Medical Director Meeting Agenda Objectives what is your ask? Disease overview Procedure/technology overview Evidence review & clinical trial plans Specific questions for payer Next Steps 13

Do s Must be part of overall reimbursement strategy Be prepared Be clear & consistent Be careful what you ask for Treat Medical Director as Customer 14

Don ts Over commit Raise the evidence bar Blow smoke Overstate outcome of meeting to commercial teams 15

Medical Director Perspective

Medical Device Companies Capital Personnel - researchers & medical workers Disease expertise - knowledge of disease states from device development process Clinical expertise - insights & outcomes from clinical trials Influence - tools & techniques to influence patients & providers Devices - clinical therapy 17

Things You Need to Know About Your Target Health Plans Structure of plan local/regional/national impacts the message Who is at risk and for what capitation/p4p Radar screen diagnoses and # lives Key decision makers bottom up vs. top down Competitive environment Political environment Coverage/Tech Assessment Process 18

Coverage/Tech Assessment Process Clinical vs. Reimbursement Usually separate process with clinical decision made first, BUT may vary with plan In most plans, a medical director chairs clinical committee process As part of process most plans use outside assessment companies (BCBS, Hayes, ECRI) Criteria: - FDA approval of technology/device - Documentation of safety - Must be as efficacious as current treatment - Improves health outcomes - Independent scientific evidence 19

Coverage/tech Assessment Process What Kick-starts the Medical Director? Outside Requests Most often from network providers Consumer Groups Patients Manufacturers Health plan staff Large employer Squeaky Wheels Process Initiation Will benefit health plan members Technology related to high utilization service or disease Will significantly reduce other health care costs And, I need to know that it s important! 20

Things to Do: Appreciate the role of the medical director I m your customer! Take the time to provide me with evidence-based information and tools to help me make an appropriate decision Make sure what you say to me is consistent with what you say to physicians and consumers KNOW YOUR STUFF! 21

More Things to Do: GET TRAINED! It is important that you understand how health plans function Learn the roles of key staff and what keeps them up at night Excellent training companies are available that have had extensive experience in the pharma industry 22

What Not to Do: Don t nag me, I m busy. I do care but I m juggling multiple projects Don t waste my time KNOW YOUR STUFF! Don t do anything that is not consistent with industry standards and ethical and legal business practices. 23

How to Influence Me Appropriately Surround Sound increase the noise level - Key opinion leaders - Local influential physicians - Clinical practice guidelines - National society evidence-based protocols - Non-branded disease awareness: increase the size of the pie benefits all patients - Practicing physician awareness: publish, present, via specialty societies - Work with employers and employer groups 24

How to Influence Me Appropriately Develop a relationship with me based on trust and mutual respect Learn best ways to communicate with me Be dedicated to my organization: research and know my plan Get involved in plan initiatives Provide value-added services that benefit the plan, providers, patients - Measurement tools to assess performance of care and services in health plans - Disease management tools - Focus on appropriate outcomes such as quality, utilization, cost, and satisfaction 25

Partner with Me Early involvement in product development, launch, and promotion Algorithms to support appropriate use Educational pieces Phase 4 trials Joint promotion of preferred devices Collaborative initiatives with plans, providers & employers 26